• Davion Healthcare completed the acquisition of medical technology intellectual property from Humaskan's four shareholders for US$ 25 million.
• The assets cover WoundSkan, a battery-free wound-monitoring dressing, and Spektra, a rapid multi-marker screening platform.
• Consideration comprises US$ 2.5 million cash and 1,730,770 new ordinary shares valued at a fixed US$ 13 per share.
• Shares will be issued January 20, 2027; cash payment is due by February 19, 2027.
• The acquisition includes commercialization rights but excludes Humaskan's corporate entity, employees and liabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DAVION HEALTHCARE PUBLIC LIMITED COMPANY published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-008102), on October 27, 2026, and is solely responsible for the information contained therein.